Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 2
2005 2
2008 2
2009 5
2010 1
2013 2
2014 1
2015 1
2016 10
2017 2
2019 3
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Bhavnani SM, Hammel JP, Lakota EA, Trang M, Bader JC, Bulik CC, VanScoy BD, Rubino CM, Huband MD, Friedrich L, Steenbergen JN, Ambrose PG. Bhavnani SM, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0221321. doi: 10.1128/aac.02213-21. Epub 2023 Mar 22. Antimicrob Agents Chemother. 2023. PMID: 36946741 Free PMC article. Clinical Trial.
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Torres A, Garrity-Ryan L, Kirsch C, Steenbergen JN, Eckburg PB, Das AF, Curran M, Manley A, Tzanis E, McGovern PC. Torres A, et al. Among authors: steenbergen jn. Int J Infect Dis. 2021 Mar;104:501-509. doi: 10.1016/j.ijid.2021.01.032. Epub 2021 Jan 20. Int J Infect Dis. 2021. PMID: 33484864 Free article. Clinical Trial.
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Lakota EA, Van Wart SA, Trang M, Tzanis E, Bhavnani SM, Safir MC, Friedrich L, Steenbergen JN, Ambrose PG, Rubino CM. Lakota EA, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e02263-19. doi: 10.1128/AAC.02263-19. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32340986 Free PMC article.
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model.
VanScoy BD, Lakota EA, Conde H, McCauley J, Friedrich L, Steenbergen JN, Ambrose PG, Bhavnani SM. VanScoy BD, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2020 May 21;64(6):e02265-19. doi: 10.1128/AAC.02265-19. Print 2020 May 21. Antimicrob Agents Chemother. 2020. PMID: 32284378 Free PMC article.
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E; OASIS-2 Investigators. O'Riordan W, et al. Among authors: steenbergen jn. Lancet Infect Dis. 2019 Oct;19(10):1080-1090. doi: 10.1016/S1473-3099(19)30275-0. Epub 2019 Aug 29. Lancet Infect Dis. 2019. PMID: 31474458 Clinical Trial.
Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Stets R, et al. Among authors: steenbergen jn. N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201. N Engl J Med. 2019. PMID: 30726692 Clinical Trial.
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. O'Riordan W, et al. Among authors: steenbergen jn. N Engl J Med. 2019 Feb 7;380(6):528-538. doi: 10.1056/NEJMoa1800170. N Engl J Med. 2019. PMID: 30726689 Clinical Trial.
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS. Popejoy MW, et al. Among authors: steenbergen jn. J Antimicrob Chemother. 2017 Jan;72(1):268-272. doi: 10.1093/jac/dkw374. Epub 2016 Oct 5. J Antimicrob Chemother. 2017. PMID: 27707990 Clinical Trial.
36 results